NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
Clinical Trials
3 trialsNCT03126643 2021-11-29
Expanded Access to Nivolumab (Opdivo)
Bristol-Myers Squibb
Approved for marketing
NCT01606982 2017-02-17
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Approved for marketing